APA (7th ed.) Citation

MP, P., IS, D., MA, R., MI, E., EG, D., GN, V., . . . NV, C. (2020). Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clinical and experimental immunology, 202(3), 353. https://doi.org/10.1111/cei.13505

Chicago Style (17th ed.) Citation

MP, Petrova, et al. "Sarcopenia and High NLR Are Associated with the Development of Hyperprogressive Disease After Second-line Pembrolizumab in Patients with Non-small-cell Lung Cancer." Clinical and Experimental Immunology 202, no. 3 (2020): 353. https://doi.org/10.1111/cei.13505.

MLA (9th ed.) Citation

MP, Petrova, et al. "Sarcopenia and High NLR Are Associated with the Development of Hyperprogressive Disease After Second-line Pembrolizumab in Patients with Non-small-cell Lung Cancer." Clinical and Experimental Immunology, vol. 202, no. 3, 2020, p. 353, https://doi.org/10.1111/cei.13505.